Abstract
Molecular modeling has contributed to drug discovery for purinergic GPCRs, including adenosine receptors (ARs) and P2Y receptors (P2YRs). Experimental structures and homology modeling have proven to be useful in understanding and predicting structure activity relationships (SAR) of agonists and antagonists. This review provides an excursus on molecular dynamics (MD) simulations applied to ARs and P2YRs. The binding modes of newly synthesized A(1)AR- and A(3)AR-selective nucleoside derivatives, potentially of use against depression and inflammation, respectively, have been predicted to recapitulate their SAR and the species dependence of A(3)AR affinity. P2Y(12)R and P2Y(1)R crystallographic structures, respectively, have provided a detailed understanding of the recognition of anti-inflammatory P2Y(14)R antagonists and a large group of allosteric and orthosteric antagonists of P2Y(1)R, an antithrombotic and neuroprotective target. MD of A(2A)AR (an anticancer and neuroprotective target), A(3)AR, and P2Y(1)R has identified microswitches that are putatively involved in receptor activation. The approach pathways of different ligands toward A(2A)AR and P2Y(1)R binding sites have also been explored. A(1)AR, A(2A)AR, and A(3)AR were utilizes to study allosteric phenomena, but locating the binding site of structurally diverse allosteric modulators, such as an A(3)AR enhancer LUF6000, is challenging. Ligand residence time, a predictor of in vivo efficacy, and the structural role of water were investigated through A(2A)AR MD simulations. Thus, new MD and other modeling algorithms have contributed to purinergic GPCR drug discovery.